Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: impact of variant replacement and waning protection during 10-month follow-up

Sara Carazo,Danuta M Skowronski,Nicholas M Brousseau,Charles-Antoine Guay,Chantal Sauvageau,Étienne Racine,Denis Talbot,Iulia G Ionescu,Judith Fafard,Rodica Gilca,Jonathan Phimmasone,Philippe De Wals,Gaston De Serres

DOI: https://doi.org/10.1101/2024.11.13.24317190

2024-11-13

Abstract:We evaluated mRNA COVID–19 vaccine effectiveness (VE) for the XBB.1.5 formulation against COVID–19 hospitalizations among adults aged ≥60 years during a ten–month follow–up period. We conducted a test–negative case–control study using Quebec population–based administrative data. Specimens collected from individuals aged ≥60 years tested at an acute–care hospital from October 2023 to August 2024 were considered test–positive cases if hospitalized for COVID–19, or controls if test–negative for SARS–CoV–2. Vaccination was defined by receipt of at least one mRNA XBB–vaccine (autumn or spring) dose. Multivariate logistic regression analyses estimated VE relative to several comparator groups, primarily those last–vaccinated in 2022, by subvariant predominant period (XBB, JN and KP), by time since XBB–vaccination and by number of XBB–vaccine doses (KP period). Participants overall and by XBB, JN and KP periods included: 5532 (4.9%) test–positive cases (1321, 1838 and 1372, respectively) and 108473 (95.1%) test–negative controls (12881, 53414 and 28595, respectively); 14584 specimens were collected during periods of subvariant cocirculation. By subvariant period, 3322 (25.8%), 27041 (50.6%) and 15401 (53.9%) controls, respectively, were considered XBB–vaccinated. Overall VE was 30% (95%CI:24–35) and by XBB, JN or KP period: 54% (95%CI:46–62), 23% (95%CI:13–32) and 0% (95%CI:-18–15), respectively. During each subvariant period, the hospitalization risk was reduced only during the first four months post–vaccination. Among individuals aged ≥60 years, mRNA XBB–vaccination provided meaningful, albeit limited and short–term, protection against COVID–19 hospitalization due to XBB, JN and KP subvariants in. Better vaccines are needed to effectively reduce COVID–19 disease burden.